Alloreactive killer cells: Hindrance and help for haematopoietic transplants

Nature Reviews Immunology

Volumn 3, Issue 2, 2003, Pages 108-122

  Parham, Peter ^a   McQueen, Karina L ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN RECEPTOR; LIGAND; ALLOANTIGEN; HLA ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; KILLER CELL IMMUNOGLOBULIN-LIKE RECEPTOR;

ALLOIMMUNITY; BONE MARROW TRANSPLANTATION; CELL KILLING; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; LEUKEMIA; LYMPHOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION; ANIMAL; BIOLOGICAL MODEL; DENDRITIC CELL; GENETICS; GRAFT VERSUS LEUKEMIA EFFECT; HISTOCOMPATIBILITY TEST; IMMUNOLOGY; LYMPHOCYTE DEPLETION; MOUSE; T LYMPHOCYTE;

ANIMALS; DENDRITIC CELLS; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; ISOANTIGENS; KILLER CELLS, NATURAL; LYMPHOCYTE DEPLETION; MICE; MODELS, IMMUNOLOGICAL; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES;

EID: 0037313360     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri999     Document Type: Review

References (147)

1. Godin, I. & Cumano, A. The hare and the tortoise: an embryonic haematopoietic race. Nature Rev. Immunol. 2, 593-604 (2002).
2. Buckley, R. H. Primary cellular immunodeficiencies. J. Allergy Clin. Immunol. 109, 747-757 (2002).
3. Thomas, E. D. & Blume, K. G. Historical markers in the development of allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant, 5, 341-346 (1999).
4. Little, M. T. & Storb, R. History of haematopoietic stem-cell transplantation. Nature Rev. Cancer 2, 231-238 (2002).
5. van Rood, J. J. & Oudshoorn, M. The quest for a bone-marrow donor - optimal or maximal HLA matching? N. Engl. J. Med 339, 1238-1239(1998).
6. Korbling, M. & Anderlini, P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cells matter? Blood 98, 2900-2908 (2001).
7. Bensinger, W. I. & Storb, R. Allogeneic peripheral blood stem-cell transplantation. Rev. Clin. Exp. Hematol. 5, 67-86 (2001).
8. Barker, J. N. & Wagner, J. E. Umbilical cord-blood transplantation: current state of the art. Curr. Opin. Oncol. 14, 160-164 (2002).
9. Thomas, E. D., Blume, K. G. & Forman, S. J. (eds) Hematopoietic Cell Transplantation (Blackwell Science Inc., Malden, Massachusetts, 1999).
10. Germain, R. N. et al. Processing and presentation of endocytically acquired protein antigens by MHC class II and class I molecules. Immunol. Rev. 151, 5-30 (1996).
11. Deeg, H. J. in A Guide to Blood and Marrow Transplantation (eds Deeg, H. J., Klingemann, H. G., Phillips, G. L. & Van Zant, G.) 127-141 (Springer-Verlag, Berlin, 1999).
12. Bortin, M. M., Horowitz, M. M. & Rimm, A. A. Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey Ann. Intern. Med. 116, 505-512 (1992).
13. Horowitz, M. H. in Hematopoietic Cell Transplantation (eds Thomas, E. D., Blume, K. G. & Forman, S. J.) 12-18 (Blackwell Science Inc., Malden, Massachusetts, 1999).
14. Goulmy E. et al. Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N. Engl. J. Med. 334, 281-285 (1996).
15. Wang, W. et al. Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein. Science 269, 1588-1590 (1995)
16. Gratwohl, A. et al. Female donors influence transplant-related mortality and relapse incidence in male recipients of sibling blood and marrow transplants. Hematol. J. 2, 363-370 (2001).
17. Goulmy, E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunol. Rev. 157, 125-140 (1997).
18. Dickinson, A. M. et al. In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens. Nature Med. 8, 410-414 (2002).
19. Mutis, T. & Goulmy, E. Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies. Semin. Hematol. 39, 23-31 (2002).
20. Blume, K. G. & Thomas, E. D. A review of autologous hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 6, 1-12 (2000).
21. Craddock, C. Haemopoietic stem-cell transplantation: recent progress and future promise. Lancet Oncol. 1, 227-234 (2000).
22. Gorin, N. C. Autologous stem-cell transplantation for adult acute leukemia. Curr. Opin. Oncol. 14, 152-159 (2002).
23. Fefer, A. in Cellular Immunotherapy of Cancer (eds Truitt, R., Gale, R. P. & Bortin, M.) 401-408 (Alan R. Liss, New York, 1987).
24. Martin, P. J. et al. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts. Blood 66, 664-672 (1985).
25. Patterson, J. et al. Graft rejection following HLA-matched T-lymphocyte depleted bone-marrow transplantation. Br. J. Haematol. 63, 221-230 (1986).
26. Horowitz, M. M. et al. Graft-versus-leukemia reactions after bone-marrow transplantation. Blood 75, 555-562 (1990).
27. den Haan, J. M. et al. Identification of a graft-versus-host disease-associated human minor histocompatibility antigen. Science 268, 1476-1480 (1995).
28. Barrett, A. J. & Malkovska, V. Graft-versus-leukaemia: understanding and using the alloimmune response to treat haematological malignancies. Br. J. Haematol. 93, 754-761 (1996).
29. Fefer, A. in Hematopoietic Cell Transplantation (eds Thomas, E. D., Blume, K. G. & Forman, S. J.) 316-326 (Blackwell Science Inc., Malden, Massachusetts, 1999).
30. Storb, R. F. et al. Non-myeloablative transplants for malignant disease. Hematology (Am. Soc. Hematol. Educ. Program) 375-391 (2001).
31. Kolb, H. J. et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 76, 2462-2465 (1990).
32. Kolb, H. J. et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow-grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood 86, 2041-2050 (1995).
33. Dazzi, F., Szydlo, R. M. & Goldman, J. M. Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem-cell transplant: where we now stand. Exp. Hematol. 27, 1477-1486 (1999).
34. Baron, F. & Beguin, Y. Preemptive cellular immunotherapy after T-cell-depleted allogeneic hematopoietic stem-cell transplantation. Biol. Blood Marrow Transplant. 8, 351-359 (2002).
35. Ferrara, J. L., Levy, R. & Chao, N. J. Pathophysiologic mechanisms of acute graft-vs-host disease. Biol. Blood Marrow Transplant. 5, 347-356 (1999).
36. Sykes, M. et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 353, 1755-1759 (1999).
37. Marmont, A. M. et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78, 2120-2130 (1991).
38. Mapara, M. Y. et al. Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells. Blood 100, 1903-1909 (2002).
39. Bensinger, W. I. & Deeg, H. J. Blood or marrow? Lancet 355, 1199-1200 (2000).
40. + stem cells induce potent specific reduction of host anti-donor cytotoxic T-lymphocyte precursors in mixed lymphocyte culture. Transplantation 65, 1386-1393 (1998).
41. + cells. Blood 99, 4174-4181 (2002).
42. Gluckman, E. et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N. Engl. J. Med. 337, 373-381 (1997).
43. Rocha, V. et al. Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood 97, 2962-2971 (2001).
44. Broxmeyer, H. E. et al. Human umbilical cord blood as a potential source of transplantable hematopoietic stem/progenitor cells. Proc. Natl Acad. Sci. USA 86, 3828-3832 (1989).
45. Rubinstein, P. et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone-marrow reconstitution. Proc. Natl Acad. Sci. USA 92, 10119-10122 (1995).
46. + cell transplants for patients with acute leukemia. Leukemia 16, 404-405 (2002).
47. Reisner, Y. Stem-cell transplantation across major genetic barriers. Ann. NY Acad. Sci. 938, 322-327 (2001).
48. Aversa, F. et al. Successful engraftment of T-cell-depleted haploidentical 'three-loci' incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 84, 3948-3955 (1994)
49. Reisner, Y. & Martelli, M. F. Stem-cell escalation enables HLA-disparate haematopoietic transplants in leukaemia patients. Immunol. Today 20, 343-347 (1999).
50. Aversa, F. et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N. Engl. J. Med 339, 1186-1193 (1998). This paper reports successful haploidentical haematopoietic-cell transplantation (HCT) in a cohort of 43 patients, using myeloablative conditioning, high numbers of stem cells and T-cell depletion. The incidence of leukaemia relapse was higher in patients with acute lymphocytic leukaemia (ALL) than in patients with acute myeloid leukaemia (AML).
51. Ruggeri, L. et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem-cell transplantation. Blood 94, 333-339 (1999). The discovery of natural killer (NK)-cell alloreactivity after HLA-mismatched transplantation when the donor has killer-cell immunoglobulin-like receptor (KIR) epitopes that are absent from the recipient. Alloreactive NK-cell clones were mainly HLA-C specific, they could kill AML cells but not ALL cells, they correlated with higher engraftment rates and they did not cause graft-versus-host disease (GVHD).
52. Valiante, N. M. et al. Functionally and structurally distinct NK-cell receptor repertoires in the peripheral blood of two human donors. Immunity 7, 739-751 (1997). Individual humans vary in terms of the KIR genes that they express. Patterns of NK-cell alloreactivity are determined by differences between KIR epitopes. This study describes the application of Klas Karre's principle of 'missing self'.
53. Ciccone, E. et al. Evidence of a natural killer (NK)-cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans. J. Exp. Med. 175, 709-718 (1992). An appreciation of the complexity and specificity of human alloreactive NK cells.
54. Dohring, C., Scheidegger, D., Samaridis, J., Cella, M. & Colonna, M. A human killer inhibitory receptor specific for HLA-A1,2. J. Immunol. 156, 3098-3101 (1996).
55. D'Andrea, A. et al. Molecular cloning of NKB1. A natural killer-cell receptor for HLA-B allotypes. J. Immunol. 155, 2306-2310 (1995).
56. Gumperz, J. E., Litwin, V., Phillips, J. H., Lanier, L. L. & Parham, P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer-cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181, 1133-1144 (1995).
57. Litwin, V., Gumperz, J., Parham, P., Phillips, J. H. & Lanier, L. L. NKB1: a natural killer cell receptor involved in the recognition of polymorphic HLA-B molecules. J. Exp. Med. 180, 537-543 (1994).
58. Colonna, M. & Samaridis, J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268, 405-408 (1995).
59. Wagtmann, N., Rajagopalan, S., Winter, C. C., Peruzzi, M. & Long, E. O. Killer-cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 8, 801-809 (1995).
60. Lee, N. et al. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A. Proc. Natl Acad. Sci. USA 95, 5199-5204 (1998).
61. Borrego, F., Ulbrecht, M., Weiss, E. H., Coligan, J. E. & Brooks, A. G. Recognition of human histocompatibility leukocyte antigen (HLA)-E complexed with HLA class I signal sequence-derived peptides by CD94/NKG2 confers protection from natural killer cell-mediated lysis J. Exp. Med. 187, 813-818 (1998).
62. Braud, V. M. et al. HLA-E binds to natural killer-cell receptors CD94/NKG2A, B and C. Nature 391, 795-799 (1998).
63. Ljunggren, H. G. & Karre, K. In search of the 'missing self': MHC molecules and NK-cell recognition. Immunol. Today 11, 237-244 (1990). This article reviews Klas Karre's 'missing self' hypothesis, which brought order to much of the phenomenology of NK-cell function. This seminal theory led to the identification of NK-cell receptors for MHC class I molecules and to other recent advances in NK-cell biology.
64. Karre, K. A perfect mismatch. Science 295, 2029-2031 (2002).
65. Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B. & Strominger, J. L. Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C. Science 260, 1121-1124 (1993).
66. Moretta, A. et al. P58 molecules as putative receptors for major histocompatibility complex (MHC) class I molecules in human natural killer (NK) cells. Anti-p58 antibodies reconstitute lysis of MHC class I-protected cells in NK clones displaying different specificities. J. Exp. Med. 178, 597-604 (1993).
67. Moretta, A. et al. Major histocompatibility complex class I-specific receptors on human natural killer and T lymphocytes. Immunol. Rev. 155, 105-117 (1997).
68. Colonna, M. Specificity and function of immunoglobulin superfamily NK-cell inhibitory and stimulatory receptors. Immunol. Rev. 155, 127-133 (1997).
69. Long, E. O. et al. Killer-cell inhibitory receptors: diversity, specificity and function. Immunol. Rev. 155, 135-144 (1997).
70. Reyburn, H. et al. Human NK cells: their ligands, receptors and functions. Immunol. Rev. 155, 119-125 (1997).
71. Winter, C. C. & Long, E. O. A single amino acid in the p58 killer-cell inhibitory receptor controls the ability of natural killer cells to discriminate between the two groups of HLA-C allotypes. J. Immunol. 158, 4026-4028 (1997).
72. Winter, C. C., Gumperz, J. E., Parham, P., Long, E. O. & Wagtmann, N. Direct binding and functional transfer of NK-cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition. J. Immunol. 161, 571-577 (1998).
73. Mandelboim, O. et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J. Exp. Med. 184, 913-922 (1996).
74. Mandelboim, O. et al. The binding site of NK receptors on HLA-C molecules. Immunity 6, 341-350 (1997).
75. Fan, Q. R., Long, E. O. & Wiley, D. C. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nature Immunol. 2, 452-460 (2001).
76. Boyington, J. C., Motyka, S. A., Schuck, P., Brooks, A. G. & Sun, P. D. Crystal structure of an NK-cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 406, 537-543 (2000).
77. Boyington, J. C., Brooks, A. G. & Sun, P.D. Structure of killer-cell immunoglobulin-like receptors and their recognition of the class I MHC molecules. Immunol. Rev. 181, 66-78 (2001).
78. Sawicki, M. W. et al. Structural basis of MHC class I recognition by natural killer cell receptors. Immunol. Rev. 181, 52-65 (2001).
79. Ruggeri, L. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295, 2097-2100 (2002) Data from 92 haploidentical transplants show that mismatching of HLA-C, which generates an alloreactive NK-cell response in the GVH direction, correlates with a much higher probability of event-free five-year survival for patients with AML, but not ALL. In a mouse model of haploidentical transplantation, alloreactive NK cells did not cause GVHD, but did kill tumour cells and recipient dendritic cells (DCs).
80. Trinchieri, G. Biology of natural killer cells. Adv. Immunol. 47, 187-376 (1989).
81. 1 mice reject bone marrow of parental origin. Although this is a phenomenon of a non-biological situation allogeneic transplantation - these authors correctly interpreted that the underlying mechanism is of biological importance.
82. Cudkowicz, G. & Bennett, M. Peculiar immunobiology of bone-marrow allografts. I. Graft rejection by irradiated responder mice. J. Exp. Med. 134, 83-102 (1971).
83. Bennett, M. Biology and genetics of hybrid resistance. Adv. Immunol. 41, 333-445 (1987).
84. Murphy, W. J., Kumar, V. & Bennett, M. Rejection of bone-marrow allografts by mice with severe combined immune deficiency (SCID) Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J. Exp. Med. 165, 1212-1217 (1987).
85. Seaman, W. E., Sleisenger, M., Eriksson, E. & Koo, G. C. Depletion of natural killer cells in mice by monoclonal antibody to NK-1.1. Reduction in host defense against malignancy without loss of cellular or humoral immunity. J. Immunol. 138, 4539-4544 (1987).
86. Kumar, V., George, T., Yu, Y. Y., Liu, J. & Bennett, M. Role of murine NK cells and their receptors in hybrid resistance. Curr. Opin. Immunol. 9, 52-56 (1997)
87. Yu, Y. Y. et al. The role of Ly49A and 5E6(Ly49C) molecules in hybrid resistance mediated by murine natural killer cells against normal T-cell blasts. Immunity 4, 67-76 (1996).
88. Gumperz, J. E. & Parham, P. The enigma of the natural killer cell. Nature 378, 246-248 (1995).
89. Shlomchik, W. D. et al. Prevention of graft-versus-host disease by inactivation of host antigen-presenting cells. Science 285, 412-415 (1999). In a mouse model, GVHD is shown to require presentation of antigen by recipient DCs to donor-derived T cells.
90. Fernandez, N. C. et al. Dendritic cells directly trigger NK-cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med. 5, 405-411 (1999).
91. + cell-derived NK-cell cytotoxicity by dendritic cells. J. Immunol. 166, 1590-1600 (2001).
92. Nishioka, Y., Hirao, M., Robbins, P. D., Lotze, M. T. & Tahara, H. Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin-12. Cancer Res. 59, 4035-4041 (1999).
93. Osada, T. et al. Peripheral-blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK-cell function. Cell. Immunol. 213, 14-23 (2001).
94. Wilson, J. L. et al. Targeting of human dendritic cells by autologous NK cells. J. Immunol. 163, 6365-6370 (1999).
95. Carbone, E. et al. Recognition of autologous dendritic cells by human NK cells. Eur. J. Immunol. 29, 4022-4029 (1999).
96. Spaggiari, G. M. et al. NK-cell-mediated lysis of autologous antigen-presenting cells is triggered by the engagement of the phosphatidylinositol 3-kinase upon ligation of the natural cytotoxicity receptors NKp30 and NKp46. Eur. J. Immunol. 31, 1656-1665 (2001).
97. Piccioli, D., Sbrana, S., Melandri, E. & Valiante, N. M. Contact-dependent stimulation and inhibition of dendritic cells by natural killer cells. J. Exp. Med. 195, 335-341 (2002). This study shows that contact-dependent interactions between activated human NK cells and immature DCs lead either to death or maturation of the DCs, depending on the ratio of NK cells to DCs.
98. Zitvogel, L. Dendritic and natural killer cells cooperate in the control/switch of innate immunity. J. Exp. Med. 195, F9-F14 (2002).
99. Ferlazzo, G. et al. Human dendritical is activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195, 343-351 (2002).
100. Ruggeri, L., Capanni, M., Martelli, M. F. & Velardi, A. Cellular therapy: exploiting NK-cell alloreactivity in transplantation. Curr. Opin. Hematol. 8, 355-359 (2001).
101. Velardi, A., Ruggeri, L., Moretta, A. & Moretta, L. NK cells: a lesson from mismatched hematopoietic transplantation. Trends Immunol. 23, 438-444 (2002).
102. Martelli, M. F. et al. Transplants across human leukocyte antigen barriers. Semin. Hematol. 39, 48-56 (2002).
103. Champlin, R. et al. Haploidentical 'megadose' stem-cell transplantation in acute leukemia: recommendations for a protocol agreed upon at the Perugia and Chicago meetings. Leukemia 16, 427-428 (2002).
104. Petersdorf, E. W. et al. Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. Blood 89, 1818-1823 (1997). For 556 North-American transplant recipients who received bone marrow from unrelated donors, HLA-C differences between donor and recipient were a risk factor for graft rejection.
105. Morishima, Y. et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B and HLA-DR matched unrelated donors. Blood 99, 4200-4206 (2002). For 1,298 Japanese transplant recipients who received haematopoietic cells from unrelated donors, HLA-C differences were an independent risk factor for GVHD.
106. El Kassar, N. et al. High resolution HLA class I and II typing and CTLp frequency in unrelated donor transplantation: a single-institution retrospective study of 69 BMTs. Bone Marrow Transplant 27, 35-43 (2001).
107. De Santis, D. et al. HLA-C KIR ligands and donor recipient KIR genotypes influence outcome of haploidentical stem-cell transplantation. Hum. Immunol. 63, S17 (2002).
108. De Santis, D. et al. Compatibility of HLA-C KIR ligands and donor recipient KIR genotypes influence outcome following single-haplotype-matched stem-cell transplantation. Tissue Antigens 59, 26s11.1 (2002).
109. Schaffer, M., Remberger, M., Ringden, O. & Olerup, O. Role of HLA-C incompatibilities in unrelated donor hematopoetic stem-cell transplantation. Tissue Antigens 59, 18s7.2 (2002).
110. Davies, S. M. et al. An evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 100, 3825-3827 (2002) A retrospective analysis that found no advantage of KIR-ligand incompatibilities in terms of the outcome of unrelated HCT with some HLA incompatibility.
111. Giebel, S. et al. KIR ligand incompatibility is associated with prolonged survival and lower transplant-related mortality in URD-HSCT recipients. Blood 100, 639 (2002).
112. Wende, H., Colonna, M., Ziegler, A. & Volz, A. Organization of the leukocyte receptor cluster (LRC) on human chromosome 19q13.4. Mamm. Genome 10, 154-160 (1999).
113. Wilson, M. J. et al. Plasticity in the organization and sequences of human KIR/ILT gene families Proc. Natl Acad. Sci. USA 97, 4778-4783 (2000).
114. Uhrberg, M. et al. Human diversity in killer-cell inhibitory receptor genes. Immunity 7, 753-763 (1997). Human genomes differ in the number of KIR genes that they contain and in the balance between the number of genes encoding inhibitory and activating receptors.
115. Trowsdale, J. et al. The genomic context of natural killer receptor extended gene families. Immunol. Rev. 181, 20-38 (2001).
116. Shilling, H. G. et al. Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype. J. Immunol. 168, 2307-2315 (2002).
117. Rajalingam, R. et al. Distinctive KIR and HLA diversity in a panel of north Indian Hindus. Immunogenetics 53, 1009-1019 (2002).
118. Shilling, H. G. et al. Genetic control of human NK-cell repertoire. J. Immunol. 169, 239-247 (2002). An individual's pattern of KIR expression by NK cells is determined mainly by the KIR type and then modified slightly by the HLA type. In HCT, KIR incompatibility is indicated for 75% of transplants from an HLA-identical, related donor and for -100% of transplants from an HLA-matched, unrelated donor.
119. Martin, M. P. et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nature Genet. 31, 429-434 (2002).
120. Shilling, H. G. et al. Reconstitution of NK-cell receptor repertoire following HLA-matched hematopoietic-cell transplantation. Blood 2 January 2003 (DOI: 10.1182/blood-2002-08-2568).
121. Rajagopalan, S. & Long, E. O. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J. Exp. Med. 189, 1093-1100 (1999).
122. Rajagopalan, S., Fu, J. & Long, E. O. Cutting edge: induction of IFN-γ production but not cytotoxicity by the killer-cell Ig-like receptor KIR2DL4 (CD158d) in resting NK cells. J. Immunol. 167, 1877-1881 (2001).
123. Faure, M. & Long, E. O. KIR2DL4 (CD158d), an NK-cell-activating receptor with inhibitory potential. J. Immunol. 168, 6208-6214 (2002).
124. Long, E. O. et al. Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158). Immunol. Rev. 181, 223-233 (2001).
125. Vales-Gomez, M., Reyburn, H. T., Erskine, R. A. & Strominger, J. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc. Natl Acad. Sci. USA 95, 14326-14331 (1998).
126. Vilches, C. & Parham, P. KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu. Rev. Immunol. 20, 217-251 (2002).
127. Norman, P. J., Stephens, H. A., Verity, D. H., Chandanayingyong, D. & Vaughan, R. W. Distribution of natural killer cell immunoglobulin-like receptor sequences in three ethnic groups. Immunogenetics 52, 195-205 (2001).
128. Norman, P. J. et al. Natural killer cell immunoglobulin-like receptor (KIR) locus profiles in African and South Asian populations. Genes Immun. 3, 86-95 (2002).
129. Toneva, M. et al. Genomic diversity of natural killer cell receptor genes in three populations. Tissue Antigens 57, 358-362 (2001).
130. Uhrberg, M., Parham, P. & Wernet, P. Definition of gene content for nine common group B haplotypes of the Caucasoid population: KIR haplotypes contain between seven and eleven KIR genes. Immunogenetics 54, 221-229 (2002).
131. Gomez-Lozano, N., Gardiner, C. M., Parham, P. & Vilches, C. Some human KIR haplotypes contain two KIR2DL5 genes: KIR2DL5A and KIR2DL5B. Immunogenetics 54, 314-319 (2002).
132. Gagne, K. et al. Relevance of KIR gene polymorphisms in bone-marrow transplantation outcome. Hum. Immunol. 63, 271-280 (2002). For HLA-matched, unrelated transplants, the incidence of GVHD was increased when the donor had a greater number of activating KIRs than the recipient. This effect was not seen for HLA-identical, related transplants.
133. Loiseau, P. et al. Impact of KIR gene polymorphism on HLA geno-identical haematopoietic cell transplantation outcome. Tissue Antigens 59, 27s11.3 (2002).
134. Chida, S., Yamashita, T., Guthrie, B., Hansen, J. A. & Geraghty, D. E. An association study between killer cell immunoglobulin-like receptor (KIR) genes and unrelated bone marrow transplant graft rejection. Tissue Antigens 59, 27s11.4 (2002).
135. Mingari, M. C., Ponte, M., Vitale, C., Bellomo, R. & Moretta, L. Expression of HLA class I-specific inhibitory receptors in human cytolytic T lymphocytes: a regulated mechanism that controls T-cell activation and function. Hum. Immunol. 61, 44-50 (2000).
136. null T cells clonally expanded in rheumatoid arthritis. J. Immunol. 165, 1138-1145 (2000)
137. Yen, J. H. et al. Major histocompatibility complex class I-recognizing receptors are disease-risk genes in rheumatoid arthritis. J. Exp. Med. 193, 1159-1167 (2001).
138. Shilling, H. G., Lienert-Weidenbach, K., Valiante, N. M., Uhrberg, M. & Parham, P. Evidence for recombination as a mechanism for KIR diversification. Immunogenetics 48, 413-416 (1998).
139. Gardiner, C. M. et al. Different NK-cell surface phenotypes defined by the DX9 antibody are due to KIR3DL1 gene polymorphism. J. Immunol. 166, 2992-3001 (2001).
140. Witt, C. S., Martin, A. & Christiansen, F. T. Detection of KIR2DL4 alleles by sequencing and SSCP reveals a common allele with a shortened cytoplasmic tail. Tissue Antigens 56, 248-257 (2000).
141. Scott, I. et al. Molecular typing shows a high level of HLA class I incompatibility in serologically well matched donor/patient pairs: implications for unrelated bone marrow donor selection Blood 92, 4864-4871 (1998).
142. Gerlach, J. A. Human lymphocyte antigen molecular typing: how to identify the 1250+ alleles out there. Arch. Pathol. Lab. Med. 126, 281-284 (2002).
143. Szydlo, R. et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings. J. Clin. Oncol. 15, 1767-1777 (1997).
144. Petersdorf, E. et al. Genomics of unrelated-donor hematopoietic-cell transplantation Curr. Opin. Immunol. 13, 582-589 (2001).
145. Petersdorf, E. W. et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 92, 3515-3520 (1998).
146. Sasazuki, T. et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N. Engl. J. Med 339, 1177-1185 (1998).
147. Petersdorf, E. W. et al. Major histocompatibility complex class I alleles and antigens in hematopoietic-cell transplantation. N. Engl. J. Med. 345, 1794-1800 (2001).